title: Opening a new GATAway for treating KRAS-driven lung tumors.
abstract: In a recent issue of Cell, Kumar and colleagues uncovered a synthetic lethal interaction between oncogenic KRAS and the transcription factor GATA2 in non-small cell lung carcinoma. Pharmacological inhibition of GATA2-mediated pathways with bortezomib and fasudil results in dramatic tumor inhibition. These observations unveil new armamentaria to fight this deadly disease.
authors.affiliation: Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), E-28029 Madrid, Spain. Electronic address: mbarbacid@cnio.es.
authors.forename: Mariano
authors.initials: M
authors.lastname: Barbacid